FDA Acting Commissioner of Food and Drugs Seeks Collaboration Between FDA and USPTO to Address Pharmaceutical Patent-Related Matters Affecting Competition

October 21, 2021

On September 10, 2021, Janet Woodcock, Acting Commissioner of the U.S. Food and Drug Administration (FDA), sent a letter to Andrew Hirshfeld, Director of the U.S. Patent and Trademark Office (USPTO), which raised several of FDA’s concerns relating to patents and competition in the pharmaceutical marketplace (“Letter”).

Read the source article at jdsupra.com
2021-10-12 16:56:00

Share This Story!